• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jules L. Dienstag


  • Snow KK, Bell MC, Stoddard AM, Curto TM, Wright EC, Dienstag JL.Processes to manage analyses and publications in a phase III multicenter randomized clinical trial.Trials. 2014;15(1):159.
  • Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC.Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.Am J Gastroenterol. 2012 Jun 12.
  • Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT, .A Functional Polymorphism in the Epidermal Growth Factor Gene is Associated with Risk for Hepatocellular Carcinoma.Gastroenterology. 2011 Mar 24.
  • Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR, .Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.Gastroenterology. 2011 Mar;140(3):840-849.e1.
  • Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT.The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.Dig Dis Sci. 2011 Feb;56(2):564-8.
  • Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, .Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial.Clin Gastroenterol Hepatol. 2010 Oct;8(10):877-83.
  • Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL, .Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.Gut. 2010 Oct;59(10):1401-9.
  • Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS, .Outcome of sustained virological responders with histologically advanced chronic hepatitis C.Hepatology. 2010 Sep;52(3):833-44.
  • Dienstag JL.Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eye.Am J Gastroenterol. 2010 Aug;105(8):1770-2.
  • Peters MG, Weinbaum C, Tan L, Baine WB, Dienstag JL, Liang TJ, So S.Recommendations for prevention, screening, and diagnosis of HBV and HCV infections.J Fam Pract. 2010 Apr;59(4 Suppl):S29-35.
  • Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL, .Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.Gastroenterology. 2010 Feb;138(2):493-502.
  • Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ, .Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.Hepatology. 2010 Feb;51(2):585-94.
  • Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL, .Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.Gastroenterology. 2010 Jan;138(1):136-46.
  • Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG, .Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.Gastroenterology. 2009 Dec;137(6):1986-94.
  • Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C, .Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.Hepatology. 2009 Dec;50(6):1738-49.
  • Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R, .Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.Hepatology. 2009 Nov;50(5):1360-9.
  • Corey KE, Servoss JC, Casson DR, Kim AY, Robbins GK, Franzini J, Twitchell K, Loomis SC, Abraczinskas DR, Terella AM, Dienstag JL, Chung RT.Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers.Infect Control Hosp Epidemiol. 2009 Oct;30(10):1000-5.
  • Dienstag JL.Benefits and risks of nucleoside analog therapy for hepatitis B.Hepatology. 2009 May;49(5 Suppl):S112-21.
  • Fontana RJ,Bonkovsky HL,Naishadham D,Dienstag JL,Sterling RK,Lok AS,Su GL.Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.Clin Gastroenterol Hepatol. 2009 Feb;7(2):219-26.
  • Di Bisceglie AM,Shiffman ML,Everson GT,Lindsay KL,Everhart JE,Wright EC,Lee WM,Lok AS,Bonkovsky HL,Morgan TR,Ghany MG,Morishima C,Snow KK,Dienstag JL.Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.N Engl J Med. 2008 Dec 4;359(23):2429-41.
  • Lok AS,Seeff LB,Morgan TR,di Bisceglie AM,Sterling RK,Curto TM,Everson GT,Lindsay KL,Lee WM,Bonkovsky HL,Dienstag JL,Ghany MG,Morishima C,Goodman ZD.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.Gastroenterology. 2009 Jan;136(1):138-48.
  • Dienstag JL.Hepatitis B virus infection.N Engl J Med. 2008 Oct 2;359(14):1486-500. Review.
  • Morishima C,Morgan TR,Everhart JE,Wright EC,Apodaca MC,Gretch DR,Shiffman ML,Everson GT,Lindsay KL,Lee WM,Lok AS,Dienstag JL,Ghany MG,Curto TM.Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.Hepatology. 2008 Nov;48(5):1412-9.
  • Dienstag JL.Relevance and rigor in premedical education.N Engl J Med. 2008 Jul 17;359(3):221-4.
  • Dienstag JL.Hepatitis a: the vaccine dividend.J Infect Dis. 2008 May 1;197(9):1220-2.
  • Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG.Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.Clin Gastroenterol Hepatol. 2008 Feb;6(2):234-41.
  • Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H Jr, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ.Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.J Viral Hepat. 2008 Feb;15(2):129-36.
  • Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC.Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.Hepatology. 2008 Mar;47(3):789-98.
  • Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG.Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.Hepatology. 2008 Feb;47(2):605-12.
  • Min AD, Dienstag JL.Oral antivirals for chronic hepatitis B.Clin Liver Dis. 2007 Nov;11(4):851-68, ix. Review.